Navigation Links
Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
Date:5/8/2013

CRANBURY, N.J., May 8, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2013 financial results on Tuesday, May 14, 2013 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 14, 2013. The conference call will include an update on development of bremelanotide for female sexual dysfunction, including plans for Phase 3 clinical trials and results of the end-of-Phase 2 meeting with the U.S. Food and Drug Administration.Schedule for the Financial Results Press Release, Conference Call / Webcast 

  • 3Q Fiscal Year 2013 Financial Results Press Release
  • 5/14/2013 at 7:30 a.m. ET

  • 3Q Fiscal Year 2013 Conference Call-Live
    Domestic Dial-In Number
    International Dial-In Number
    Passcode
  • 5/14/2013 at 11:00 a.m. ET

    1-888-427-9419

    1-719-457-2648

    8591699

  • 3Q Fiscal Year 2013 Conference Call-Replay
    Domestic Dial-In Number
    International Dial-In Number
    Passcode
  • 5/14/2013-5/21/2013

    1-888-203-1112

    1-719-457-0820

    8591699

  • Webcast Live and Replay Access
  • http://www.palatin.com The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts"

    section of Palatin's website at http://www.palatin.comAbout Palatin Technologies, Inc.
    Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information, please visit http://www.palatin.com or follow us on Twitter at '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2

    Related biology technology :

    1. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
    2. Palatin Technologies To Present At The 25th Annual ROTH Conference
    3. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
    4. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
    5. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
    6. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
    7. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
    9. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    10. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
    11. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... addition of the "Global N-acetylcysteine Industry Report ... The Global N-acetylcysteine Industry Report 2014 is ... state of the global N-acetylcysteine industry. ... industry including definitions, classifications, applications and industry chain ...
    (Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... a FM-4910 listed material, to stay competitive in ... These high-performance materials ultimately impact product quality ... President and owner. , Established in 1980 in ... strong as many fabricators have left the business. ...
    (Date:9/18/2014)...  Neogen Corporation (Nasdaq: NEOG ) announced ... with Merck Animal Health to market Neogen,s Igenity ® ... Dairy Heifer Program consists of genomic tests that offer ... of replacement dairy heifers. The genomic tests can be ... an excellent tool in the decision-making process for breeding ...
    (Date:9/18/2014)... Sept. 18, 2014   Sigma-Aldrich Corporation ... has entered into a new gene editing partnership ... Vector Core. Under the partnership, Sigma-Aldrich will provide ... design consultation, and dedicated gene editing bioinformaticians. ... editing-based research at the U-M Medical School. One ...
    Breaking Biology Technology:Global N-acetylcysteine Industry Report 2014 2Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Merck Animal Health to market Neogen's dairy genomic program 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
    ... LIBREVILLE, Gabon, December 2 ... Africa: Everyone,s Problem and Heritage" , ... June 2010 the,Gabonese Republic is hosting an international conference ... in Africa. The,conference will be attended by government and ...
    ... , ... an event bringing together the leaders in technology development ... announced the December 11th deadline for technology abstracts and ... World, in association with the Nano Science and Technology ...
    ... , SINGAPORE, Dec. 2 S*BIO Pte Ltd today ... at The American Society of Hematology 51st Annual Meeting and ... the clinical results from the Phase 1 dose-escalation trial of ... dose levels ranging from 100 to 600 mg. These doses ...
    Cached Biology Technology:Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
    (Date:9/18/2014)... tonight at the third annual Golden Goose Award ceremony ... infants and in paving the way for the telecommunications ... by the National Science Foundation, the National Institutes of ... honored at a ceremony at the Library of Congress ... Congress will be on hand to help present their ...
    (Date:9/18/2014)... are too stressed they are often grouchy, grumpy, nasty, ... (BMI) at EPFL have just highlighted a fundamental synaptic ... the loss of social skills and cognitive impairment. When ... molecule in the brain. This was revealed by a ... Carmen Sandi,s team went to look for answers in ...
    (Date:9/18/2014)... their entire lives nestling in the protective tentacles of ... they sometimes travel hundreds of kilometres across the open ... fish has been predicted, this is the first time ... populations has been observed. , Dr Steve Simpson, Senior ... University of Exeter, and colleagues from the Australian Research ...
    Breaking Biology News(10 mins):3rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2How stress tears us apart 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3
    ... the human gut adaptively shifts more than a quarter ... diet changes from sugar to complex carbohydrates. , This ... survive rapidly changing nutrient conditions but also helps maintain ... microbial society, according to researchers at Washington University School ...
    ... Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced ... "Multiplexed Active Biologic Array" by the U.S. Patent and ... of addressing one or more electrodes (or "test sites") ... patent also covers a method for storing the value ...
    ... owners because of their vibrant colors. But those colors may ... For more than a century, biochemists have known that parrots ... of plumage colors, but their biochemical identity has remained elusive. ... behind the colors of parrots, describing on a molecular level ...
    Cached Biology News:Highly adaptable genome in gut bacterium key to intestinal health 2Highly adaptable genome in gut bacterium key to intestinal health 3Nanogen Issued Patent for Electronic Microarray With Memory 2Transport System Smuggles Medicines Into Brain 2Transport System Smuggles Medicines Into Brain 3
    ... Odyssey images are easily imported for data analysis , ... ... Extensive background and signal options to optimize, ... results , ...
    ... UltraPure Agarose and SYBR Safe DNA Gel Stain ... Saves money versus buying these same products separately ... alternative to ethidium bromide ... Agarose resolves DNA and RNA fragments from 100 bp ...
    ... E.Coli glycerol stocks contained in standard 96-well ... clones with approximately 5,000 clones per plate. ... plate well, the corresponding subplate is screened ... the positive well(s). Cells from a positive ...
    ... ml per liter of urine will give a ... BMD dipstick. ,Certification: The Donors are of ... to be NEGATIVE for HbsAg, HCV, HIV-1 & ... FDA methods. THIS MATERIAL IS SOLD FOR IN-VITRO ...
    Biology Products: